相似文献
1
Molecular pathogenesis of pulmonary arterial hypertension.
J Clin Invest. 2008 Jul;118(7):2372-9. doi: 10.1172/JCI33452.
2
Mediators involved in HIV-related pulmonary arterial hypertension.
AIDS. 2008 Sep;22 Suppl 3:S41-7. doi: 10.1097/01.aids.0000327515.55041.da.
3
Molecular pathogenesis of pulmonary arterial hypertension.
J Clin Invest. 2012 Dec;122(12):4306-13. doi: 10.1172/JCI60658. Epub 2012 Dec 3.
4
Pulmonary arterial hypertension: the clinical syndrome.
Circ Res. 2014 Jun 20;115(1):115-30. doi: 10.1161/CIRCRESAHA.115.301146.
5
Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Stem Cell Res Ther. 2017 Feb 10;8(1):34. doi: 10.1186/s13287-017-0480-y.
6
Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials.
Pharmacol Ther. 2010 Apr;126(1):1-8. doi: 10.1016/j.pharmthera.2009.12.006. Epub 2010 Feb 1.
7
BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Cell Mol Life Sci. 2017 Aug;74(16):2979-2995. doi: 10.1007/s00018-017-2510-4. Epub 2017 Apr 26.
8
Pathology of pulmonary hypertension.
Clin Chest Med. 2007 Mar;28(1):23-42, vii. doi: 10.1016/j.ccm.2006.11.010.
9
New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.
Chest. 2015 Feb;147(2):529-537. doi: 10.1378/chest.14-0862.
10
Recent advances in the treatment of pediatric pulmonary artery hypertension.
Pediatr Clin North Am. 1999 Apr;46(2):331-45. doi: 10.1016/s0031-3955(05)70121-8.
引用本文的文献
1
Lactate Metabolism and Lactylation Modification: New Opportunities and Challenges in Cardiovascular Disease.
MedComm (2020). 2025 Jul 1;6(7):e70269. doi: 10.1002/mco2.70269. eCollection 2025 Jul.
2
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases.
MedComm (2020). 2025 Jun 25;6(7):e70120. doi: 10.1002/mco2.70120. eCollection 2025 Jul.
3
Repurposing of modafinil as an anti-inflammatory drug: a systematic review of experimental studies.
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 13. doi: 10.1007/s00210-025-03964-9.
4
PPARγ/ETV2 axis regulates endothelial-to-mesenchymal transition in pulmonary hypertension.
Pulm Circ. 2024 Oct 10;14(4):e12448. doi: 10.1002/pul2.12448. eCollection 2024 Oct.
5
Hormonal influence: unraveling the impact of sex hormones on vascular smooth muscle cells.
Biol Res. 2024 Sep 4;57(1):61. doi: 10.1186/s40659-024-00542-w.
6
Systemic juvenile idiopathic arthritis-associated lung disease: A retrospective cohort study.
World J Clin Pediatr. 2024 Mar 9;13(1):88912. doi: 10.5409/wjcp.v13.i1.88912.
7
Microvascular smooth muscle cells exhibit divergent phenotypic switching responses to platelet-derived growth factor and insulin-like growth factor 1.
Microvasc Res. 2024 Jan;151:104609. doi: 10.1016/j.mvr.2023.104609. Epub 2023 Sep 15.
8
PGC-1α-mediated angiogenesis prevents pulmonary hypertension in mice.
JCI Insight. 2023 Sep 8;8(17):e162632. doi: 10.1172/jci.insight.162632.
9
Resistin-like Molecule α and Pulmonary Vascular Remodeling: A Multi-Strain Murine Model of Antigen and Urban Ambient Particulate Matter Co-Exposure.
Int J Mol Sci. 2023 Jul 25;24(15):11918. doi: 10.3390/ijms241511918.
10
Imaging the TGFβ type I receptor in pulmonary arterial hypertension.
EJNMMI Res. 2023 Mar 22;13(1):23. doi: 10.1186/s13550-023-00966-7.
本文引用的文献
1
An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.
J Clin Invest. 2008 May;118(5):1846-57. doi: 10.1172/JCI32503.
2
Pulmonary arterial remodeling induced by a Th2 immune response.
J Exp Med. 2008 Feb 18;205(2):361-72. doi: 10.1084/jem.20071008. Epub 2008 Jan 28.
3
Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension.
Am J Pathol. 2008 Jan;172(1):256-64. doi: 10.2353/ajpath.2008.070395. Epub 2007 Dec 21.
4
Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin.
Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L276-89. doi: 10.1152/ajplung.00414.2007. Epub 2007 Dec 14.
5
Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling.
Circ Res. 2008 Feb 15;102(3):380-8. doi: 10.1161/CIRCRESAHA.107.161059. Epub 2007 Dec 13.
6
A USA-based registry for pulmonary arterial hypertension: 1982-2006.
Eur Respir J. 2007 Dec;30(6):1103-10. doi: 10.1183/09031936.00042107. Epub 2007 Sep 5.
7
The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted.
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11418-23. doi: 10.1073/pnas.0610467104. Epub 2007 Jun 27.
8
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology.
Am Heart J. 2007 Jun;153(6):1037-47. doi: 10.1016/j.ahj.2007.02.037.
9
The value of approved therapies for pulmonary arterial hypertension.
Am Heart J. 2007 Jun;153(6):889-90. doi: 10.1016/j.ahj.2007.03.001.
10
Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension.
Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L548-54. doi: 10.1152/ajplung.00428.2006. Epub 2007 May 25.
Zotero 插件